Heroin use has become pervasive in all sectors, inner cities, suburbs and rural areas. It is no longer an isolated problem, according to a study published in JAMA Psychiatry.
Dr CiceroHeroin use has become pervasive in all sectors, inner cities, suburbs and rural areas. It is no longer an isolated problem, according to a study published in JAMAPsychiatry.
Theodore J. Cicero, PhD, professor of psychiatry at Washington University in St Louis, and his colleagues found that heroin users are increasingly likely to be white, from nonurban areas and to have previously abused prescription pain drugs.
Cicero and colleagues used standardized surveys of 10,000 people entering treatment and detailed qualitative interviews with a subset of these individuals to address the drugs they had used in the last 30 days and the motivation for such use.
“Our studies show that heroin abuse, once a problem with male minority populations in inner cities [1960 to 1970], has migrated to suburban and rural locations where it is now pervasive in predominately [>90%] white, middle- to upper-class young males and females in their mid-20s,” Cicero said.
Prior to the 1980s, heroin users were roughly equally divided between white and minority groups, the authors noted.
“Most importantly, today most heroin abusers were introduced to opioids through abuse of prescription opioid drugs, such as OxyContin, Percocet, and Vicodin first and then graduated to heroin, often as a cheaper and more readily accessible alternative than their prescription opioid of choice,” he said. “The latter have grown more expensive while heroin has become cheaper.”
“As the use of prescription opioid analgesics has increased over the years so too has diversion to illicit channels where they are used for non-therapeutic purposes [eg, to get high],” said Dr Cicero. “As research moves forward it will be important to define those individuals most at risk to develop opioid abuse problems.”
FDA Approves Xolremdi for Ultra Rare Immune Disorder
April 29th 2024Xolremdi is the first therapy for WHIM syndrome, which can cause recurrent lung infections and papillomavirus-related warts. It’s available in two doses: 400 mg for an annual cost of $496,400 and 300 mg for an annual cost of $372,300.
FDA Approves Pfizer’s Gene Therapy Beqvez for Hemophilia
April 26th 2024Beqvez (fidanacogene elaparvovec) is priced at $3.5 million, which is on parity with Hemgenix, the first one-time therapy to treat adults with hemophilia B. Pfizer’s warranty will refund insurers and continue to provide coverage for patients if they change insurers.